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Objectives
To evaluate the effect of peri-operative blood transfusion (PBT) on recurrence-free survival, overall survival, cancerspecific mortality and other-cause mortality in patients undergoing radical cystectomy (RC), using a contemporary European multicentre cohort.
Patients and Methods
The Prospective Multicentre Radical Cystectomy Series (PROMETRICS) includes data on 679 patients who underwent RC at 18 European tertiary care centres in 2011. The association between PBT and oncological survival outcomes was assessed using Kaplan-Meier, Cox regression and competing-risks analyses. Imbalances in clinicopathological features between patients receiving PBT vs those not receiving PBT were mitigated using conventional multivariable adjusting as well as inverse probability of treatment weighting (IPTW).
Results
Overall, 611 patients had complete information on PBT, and 315 (51.6%) received PBT. The two groups (PBT vs no PBT) differed significantly with respect to most clinicopathological features, including peri-operative blood loss: median (interquartile range [IQR] ) 1000 (600-1500) mL vs 500 (400-800) mL (P < 0.001). Independent predictors of receipt of PBT in multivariable logistic regression analysis were female gender (odds ratio [OR] 5.05, 95% confidence interval [CI] 2.62-9.71; P < 0.001), body mass index (OR 0.91, 95% CI 0.87-0.95; P < 0.001), type of urinary diversion (OR 0.38, 95% CI 0.18-0.82; P = 0.013), blood loss (OR 1.32, 95% CI 1.23-1.40; P < 0.001), neoadjuvant chemotherapy (OR 2.62, 95% CI 1.37-5.00; P = 0.004), and ≥pT3 tumours (OR 1.59, 95% CI 1.02-2.48; P = 0.041). In 531 patients with complete data on survival outcomes, unweighted and unadjusted survival analyses showed worse overall survival, cancer-specific mortality and other-cause mortality rates for patients receiving PBT (P < 0.001, P = 0.017 and P = 0.001, respectively). After IPTW adjustment, those differences no longer held true. PBT was not associated with recurrencefree survival (hazard ratio [HR] 0.92, 95% CI 0.53-1.58; P = 0.8), overall survival (HR 1.06, 95% CI 0.55-2.05; P = 0.9), cancer-specific mortality (sub-HR 1.09, 95% CI 0.62-1.92; P = 0.8) and other-cause mortality (sub-HR 1.00, 95% CI 0.26-3.85; P > 0.9) in IPTW-adjusted Cox regression and competing-risks analyses. The same held true in conventional multivariable Cox and competing-risks analyses, where PBT could not be confirmed as a predictor of any given endpoint (all P values >0.05).
Conclusion
The present results did not show an adverse effect of PBT on oncological outcomes after adjusting for baseline differences in patient characteristics.
Keywords blood transfusion, cystectomy, propensity score, recurrence, survival Radical cystectomy (RC) with bilateral pelvic lymph node dissection is the standard of care in muscle-invasive nonmetastatic bladder cancer and is indicated in recurrent highrisk non-muscle-invasive disease [1] . Nevertheless, the procedure is associated with significant morbidity, intraoperative blood loss and considerable peri-operative blood transfusion (PBT) rates, ranging from 15% up to 66% [2] [3] [4] . Despite its potentially life-saving features, PBT entails significant risks, such as transfusion-related lung injury, the transmission of infectious agents, and allergic reactions [5] . Unrestricted use of PBT is even more controversial in surgical oncology, as a potential adverse effect on oncological outcomes in patients with cancer undergoing curative surgery has been suggested. This concerning association has been demonstrated in several malignancies, including colorectal [6] , hepatocellular [7] and pancreatic cancer [8] . The postulated underlying mechanisms are manifold and are attributed to transfusion-related immunomodulation [9] , inflammatory response [10] , intraoperative release of circulating tumour cells [11, 12] and decreased host immunity resulting from anaesthetics and opioids [13] . Those severe effects were not confirmed, however, in other selected malignancies, such as prostate [14, 15] or cervical cancer [16] . Remarkably, in patients undergoing RC for bladder cancer, highly conflicting results have been reported over the last two decades. While PBT administration per se, as well as its timing, was associated with impaired oncological outcomes and overall survival in some studies [17] [18] [19] [20] [21] , other studies were not able to confirm this association [22] [23] [24] .
Differences among patient cohorts as well as methodological barriers rather than PBT itself have been postulated as the cause of the observed impaired outcomes [19, 23] . In fact, when assessing the effect of administration of PBT on any oncological outcome, a major challenge lies in the multiplicity of confounders and their high degree of interdependence. Overfitting and residual confounding, therefore, pose a source of inaccuracy in conventional multivariable regression analysis.
The aim of the present study was to assess the impact of PBT on oncological outcomes in a large multi-institutional contemporary cohort of patients treated with RC, using both conventional multivariable and inverse probability of treatment weighting (IPTW) regression analyses.
Patients and Methods

Study Population
We relied on the Prospective Multicentre Radical Cystectomy Series (PROMETRICS) 2011, a prospectively collected data pool of 679 men and women undergoing RC for high-grade non-muscle-invasive or muscle-invasive bladder cancer at 18 tertiary care centres in Germany, Austria and Italy between 1 January 2011 and 31 December 2011. This dataset is an institutional review board-approved study, as all cooperating centres provided compulsory data sharing agreements. For the purpose of the study, patients with missing information on PBT as well as those with clinically metastatic disease (cM1) were excluded before analyses. This yielded a study population of 611 patients.
Data Assessment and Covariates
Clinicopathological patient characteristics were assessed and documented at the time of surgery and consisted of age, gender, American Society of Anesthesiologists (ASA) physical status, age-adjusted Charlson comorbidity index, body mass index (BMI), number of lymph nodes removed, type of urinary diversion, pathological T and N stage according to the 2009 TNM classification [25] , soft tissue surgical margin status, presence of lymphovascular invasion, administration of peri-operative chemotherapy (neoadjuvant and adjuvant), any complication within 30 days of RC, defined based on the classification as described by Clavien and Dindo [26] , and estimated blood loss. Pathological grade was not explicitly reported, as most patients harboured high-risk disease. The overall estimated blood loss was a compound variable incorporating intra-operative and postoperative blood loss. PBT was defined as any transfusion of allogeneic red blood cells during RC or within the postoperative inpatient stay. PBT hinged on the clinician's discretion because no interinstitutional standards for intra-or postoperative thresholds for transfusion were applied. Covariates were coded as indicated in Table 1 .
Endpoints and Outcomes
Primary study endpoints were disease recurrence-free survival and overall survival, which were defined as the time from RC to diagnosis of local or distant disease recurrence and to
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© 2017 The Authors BJU International © 2017 BJU International death from any cause, respectively. Secondary endpoints were bladder cancer-specific mortality and other-cause mortality. We compared all the aforementioned outcomes in patients who received PBT with those who did not receive PBT.
Statistical Analyses
Our statistical analyses consisted of several steps. First, variables coded continuously were reported using means and SD values or medians and interquartile ranges (IQRs), while categorical variables were reported as frequencies and proportions. The study population was stratified according to receipt of PBT vs no PBT, and Pearson's chi-squared test, Student's t-test and the Mann-Whitney U-test were used, as appropriate, to compare categorical and continuous covariates between the two groups.
Second, to identify clinicopathological factors associated with the receipt of PBT, we estimated the crude odds ratios (ORs) for all available covariates in univariable logistic regression analyses, which were then further evaluated in a multivariable logistic regression model using all available characteristics.
Third, in all patients with complete information on follow-up, disease recurrence and survival data, unadjusted KaplanMeier curves were calculated to compare disease recurrencefree survival and overall survival rates in patients who received PBT and in those who did not. Equality of the survival curves was tested using the log-rank test. In addition, unadjusted cumulative incidence curves to compare cancer-specific mortality and other-cause mortality (PBT vs no PBT) were calculated using a univariable competingrisks regression model according to Fine and Gray [27] . Equality of cumulative incidences was assessed using the Pepe-Mori test.
Fourth, multivariable Cox proportional hazard regression models were developed to evaluate the association of PBT with disease recurrence-free survival and overall survival, accounting for clinicopathological covariates. A multivariable competing-risks regression model according to Fine and Gray [27] was used to control for informative censoring in cancerspecific mortality and the aforementioned clinicopathological covariates. Proportional subhazards of cancer-specific mortality for both groups (PBT vs no PBT) were estimated accounting for other-cause mortality and vice versa. All regression analyses were clustered by facility and adjusted for annual hospital caseload to account for variation in baseline characteristics on a facility level.
Fifth, we performed a sensitivity analysis to mitigate imbalances between the clinicopathological characteristics of patients who received PBT and those who did not. To approximate randomization regarding the receipt of PBT mathematically, we controlled for the aforementioned imbalances using an IPTW analysis [28] . Specifically, the propensity of receiving PBT vs not receiving PBT was estimated from a logistic regression model including all available clinicopathological covariates. Each patient was further weighted by the inverse probability of being in the PBT vs the no PBT group to balance out observable characteristics. The balance in significant covariates, included in the propensity score model, between the weighted groups was assessed using the standardized differences approach and by comparing their distribution with unweighted data. Subsequently, IPTW-adjusted Kaplan-Meier curves were calculated to compare disease recurrence-free survival and overall survival between the treatment groups, and equality was tested using an IPTW-adjusted log-rank test. Univariable Cox regression analyses were performed to calculate IPTWadjusted hazard ratios (HRs) of the PBT effect. Likewise, IPTW-adjusted cumulative incidences and proportional subhazards of bladder cancer-specific mortality accounting for other-cause mortality (and vice versa) were estimated. Equality of the cumulative incidence curves was tested using a modified log-rank test. To eliminate residual imbalance in prognostically important covariates, we performed additional sensitivity analyses by using multivariable regression adjustment after IPTW [29] .
All statistical analyses were performed using STATA â (version 14; StataCorp LP, College Station, TX, USA). Two-sided statistical significance was defined as P value < 0.05.
Results
Of 611 patients undergoing RC for bladder cancer, 315 (51.6%) received PBT, with a median (IQR) number of units transfused of 2 (2-4). Patients differed between the two groups with respect to most clinicopathological characteristics (Table 1) . Patients who received PBT had greater blood loss (median [IQR] 1000 [600-1500] mL) than those who did not receive a PBT (median [IQR] 500 [400-800] mL; P < 0.001).
Characteristics Associated with Peri-operative Blood Transfusion
Results from univariable and multivariable logistic regression analyses are reported in Table 2 . The majority of covariates showed a significant association with the receipt of PBT in univariable models; however, only female gender (OR 5.05, 95% CI 2.62-9.71; P < 0.001), BMI (OR 0.91, 95% CI 0.87-0.95; P < 0.001), type of urinary diversion (OR 0.38, 95% CI 0.18-0.82; P = 0.013), estimated blood loss (OR 1.32, 95% CI 1.23-1.40; P < 0.001), pathological tumour stage ≥pT3 (OR 1.59, 95% CI 1.02-2.48; P = 0.041) and neoadjuvant chemotherapy (OR 2.62, 95% CI 1.37-5.00; P = 0.004) remained independent predictors of receipt of PBT in multivariable analysis (Table 2) .
Unweighted Survival Analyses
Follow-up, recurrence and survival data were available in 531 patients. At a median (IQR) follow-up of 26 (21-30) months, 104 patients had disease recurrence (19.6%), 104 patients had died from bladder cancer (19.6%), and 148 patients had died from any cause (27.9%). Unadjusted Kaplan-Meier curves showed that disease recurrence-free survival was not different between the groups (P = 0.6; Fig. 1A ), whereas overall survival curves differed significantly between patients who received PBT vs no PBT (median time to overall survival not estimable in both groups; P < 0.001 [ Fig. 1B]) . When accounting for other-cause mortality in unadjusted competing-risks analyses, a significant increase in cumulative incidences of cancer-specific mortality was observed with PBT vs no PBT (P = 0.017; Fig. 1C) , and a similar adverse effect regarding increased other-cause mortality in the PBT group was seen when accounting for cancer-specific mortality (P = 0.001; Fig. 1D ). After adjusting for clinicopathological covariates in multivariable regression analyses, the receipt of PBT could not be identified as an independent predictor of disease recurrence (HR 0.96, 95% CI 0.54-1.70; P = 0.9), overall mortality (HR 1.34, 95% CI 0.90-1.99; P = 0.2), cancerspecific mortality (subhazard ratio (SHR) 1.03, 95% CI 0.57-1.87; P > 0.9), or other-cause mortality (SHR 2.16, 95% CI 0.99-4.74; P = 0.054 [ Table 3 ]). Higher pathological T stage, number of lymph nodes removed, presence of lymphovascular invasion, and lower annual hospital caseload were adversely associated with overall and cancer-specific mortality, whereas BMI and any complication within 30 days were the only cofactors adversely affecting other-cause mortality (Table 3) .
Weighted Survival Analyses
After IPTW adjustment, standardized difference analyses showed that the distribution of clinicopathological covariates included in the propensity score model was similar in the . 5
Cancer-specific mortality (cumulative incidence) Other-cause mortality (cumulative incidence) P < 0.001 PBT and no PBT group (Fig. 2) . IPTW-adjusted KaplanMeier and cumulative incidence curves (Fig. 3) showed that there was no difference between patients who received PBT vs no PBT regarding the median time to disease recurrence (P = 0.8; Fig. 3A ), overall survival (P = 0.9; Fig. 3B ), cancerspecific mortality (P = 0.8; Fig. 3C ), and other-cause mortality (P > 0.9; Fig. 3D ). Finally, in univariable IPTWadjusted Cox regression analyses, PBT was not associated with disease recurrence (HR 0.92, 95% CI 0.53-1.58; P = 0.8) or overall survival (HR 1.06, 95% CI 0.55-2.05; P = 0.9). Similarly, no association between PBT and cancer-specific mortality (SHR 1.09, 95% CI 0.62-1.92; P = 0.8) and othercause mortality (SHR 1.00, 95% CI 0.26-3.85; P > 0.9) was found in univariable IPTW-adjusted competing-risks regression analysis. Similar results were found in sensitivity analyses, when performing multivariable regression after IPTW (Table S1 ).
Discussion
First described almost four decades ago [30] , the adverse effect of PBT on survival in oncological patients remains controversial. Conflicting results have been published for most solid non-urological and urological tumours, including kidney [31] and bladder cancer [20, 32] . We therefore sought to assess the impact of PBT on survival in a contemporary, multicentre European cohort of patients undergoing RC. We found PBT to be significantly associated with overall and cancer-specific mortality in unadjusted Kaplan-Meier and regression analyses; however, after IPTW adjustment for known confounders, this association no longer held true for either endpoint.
In the peri-operative period, a multitude of measurable and immeasurable confounders inherent to the surgical process and the disease pathology need to be considered, apart from PBT, when assessing the effect of PBT on oncological outcomes. Specifically, extirpative surgery may lead to the release of circulating tumour cells and proliferation inducers via surgical manipulation [33, 34] . Peri-operative stress, as well as postoperative pain and several mainstay anaesthetics have been shown to promote metastatic growth by suppression of natural killer cell activity [13] . Further evidence suggests, that morphine, and its derivatives, which are routinely used to manage postoperative pain, also promote angiogenesis and tumour growth [13] .
Several notable points were demonstrated in the present study. Firstly, the distribution of advanced disease characteristics, such as pT and N+ stage, and rates of PBT in the study cohort did not limit us in assessing a possible correlation between PBT and oncological outcomes. A look at the distribution of advanced disease characteristics in cohorts that did show an impact of PBT on survival, such as those in the studies by Linder et al. [20] (40% pT3/4, 16% pN+) and Moschini et al. [17] (58% pT3/4, pN stage not available), and those that did not, such as in Morgan et al. [19] (51% pT3/4, 24% pN+) and Kluth et al. [23] (51% pT3/4, 30% pN+) reveals great heterogeneity. The distribution of these features was, however, similar to that in the present study cohort (43% pT3/4, and 23% pN+). Intriguingly, PBT rates (52%) in the present population were among the highest published so far in bladder cancer and are only surpassed by those of Linder et al. [20] (62%) and Abel et al. [18] (67%). Secondly, we showed that the necessity of PBT is probably a proxy for advanced stage disease and comorbidity. Apart from the significant differences in clinicopathological features, including blood loss, ASA status, and pathological T stage between recipients and non-recipients of PBT (Table 1) ; female gender, lower BMI, estimated blood loss and neoadjuvant chemotherapy independently predicted PBT. Previous studies have shown an association of female gender with presentation at an advanced disease stage, recurrence and cancer-specific survival after RC [19, 20] . Decreasing BMI, however, is linked to inferior outcomes in colorectal, breast and bladder cancer alike [35] [36] [37] . Reasons for the association between blood loss and progressive disease are advanced tumour stage and invasiveness, which make surgical resection more demanding, resulting in greater blood loss [38] . Taken together, the necessity for PBT indicates a higher burden of disease and comorbidities that lead to inferior survival, regardless of PBT administration. This assertion was confirmed, when we found the adverse effect of PBT on both cancer-specific and othercause mortality vanished after accounting for imbalances in disease characteristics in IPTW-adjusted competing-risks analyses. Adjusting for the numerous measurable confounders has proven difficult previously [19, 23] . In conventional multivariable analyses, it poses the risk of overfitting, depending on the cohort size and number of events. Further, a high degree of multi-collinearity between factors that affect the receipt of PBT and survival might persist even after adjustment, which eventually leads to a biased treatment effect observed. This has led previous authors to doubt the suitability of multivariable analyses and suggest different methodology [19, 23, 39] . The novelty and strength of the present study lies in the combined methodology of IPTW and competing-risks analyses. Differences in either oncological endpoints in our cohort were levelled after applying IPTW-adjustment.
Finally, a look at other cancer entities reveals a similar heterogeneity in study outcomes. To date, two large randomized controlled trials have evaluated the impact of PBT on oncological outcomes [40, 41] . To avoid the bias carried by the disease burden, patients with colorectal cancer undergoing curative surgery and in need of PBT were randomized to receive either allogeneic or autologous blood, and no difference in oncological outcomes was found between the groups [41] . Recurrence rates were not significantly different (23% vs 26%) even after incorporation into a meta-analysis [39] . Patients with prostate cancer undergoing curative surgery tend to be After IPTW Before IPTW younger and have a greater life expectancy than their bladder cancer counterparts, which might further limit potential confounders such as comorbidities and advanced disease characteristics [42] . Nevertheless, contemporary retrospective studies in prostate cancer cohorts undergoing curative surgery do not support an adverse effect of PBT on disease recurrence, cancer-specific and overall mortality [14, 43, 44] . The authors compared receipt of autologous and allogeneic PBT with nonreceipt and, in addition to known confounders, adjusted for the type of anaesthesia [43, 44] .
Despite its methodological strengths, the present study should be interpreted within the limitations of an observational study design. Although patient data were collected prospectively, we cannot preclude residual confounding in the form of unmeasured differences in baseline characteristics. In this regard, it is possible that inadvertent biases were introduced by excluding patients with missing data on follow-up or recurrence and survival information. Likewise, a limited sample size may have affected the identification of independent predictors in conventional multivariable analyses by the potential occurrence of interactions between covariates, thus, masking statistical significance in certain variables. Furthermore, as this is a multi-institutional study, we did not perform central pathological review. RC was performed by different surgeons and PBT was administered at the discretion of each physician. All patients were treated at academic centres by uro-oncologists, however, and baseline as well as follow-up data were collected according to a .05 0 Cancer-specific mortality (cumulative incidence) Other-cause mortality (cumulative incidence) P = 0.8 P = 0.9 P > 0.9
No PBT PBT Fig. 3 Inverse probability of treatment weighting-adjusted Kaplan-Meier curves depicting (A) disease recurrence-free survival and (B) overall survival, and adjusted cumulative incidence curves depicting (C) cancer-specific mortality and (D) other-cause mortality in the weighted study population, stratified by administration of peri-operative blood transfusion (PBT).
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© 2017 The Authors BJU International © 2017 BJU International standardized protocol. To mitigate this variability on the facility level, all multivariable analyses were adjusted for hospital caseload and clustered by facility. Finally, we were not able to adjust for preoperative haemoglobin levels or the exact timing of PBT.
In conclusion, univariable analyses showed a significant association between the administration of PBT, inferior oncological outcome, and other-cause mortality among patients undergoing RC; however, after imbalances in patient characteristics between recipients and non-recipients of PBT were adjusted for using an IPTW approach, this association no longer held true. A greater burden of disease and comorbidities, regardless of administration of PBT, were the key drivers of inferior survival in the present analysis.
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